[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Sikoski P, Trybus J, Cline JM, Muhammad FS, Eckhoff A, Tan J, Lockard M, Jolley T, Britt S, Kock ND: Cystic mammary adenocarcinoma associated with a prolactin-secreting pituitary adenoma in a New Zealand white rabbit (Oryctolagus cuniculus). Comp Med; 2008 Jun;58(3):297-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic mammary adenocarcinoma associated with a prolactin-secreting pituitary adenoma in a New Zealand white rabbit (Oryctolagus cuniculus).
  • Pituitary adenoma in a rabbitA 44-mo-old, female, nulliparous New Zealand White Rabbit (Oryctolagus cuniculus) presented with bilaterally diffusely enlarged mammary glands with enlarged, discolored teats that exuded brown, mucoid discharge.
  • Computed tomography and serum prolactin levels supported the diagnosis of mammary gland dysplasia, possibly due to a prolactin-secreting pituitary adenoma.
  • Histologic evaluation confirmed the presence of a pituitary adenoma, mammary hyperplasia, dysplasia, and cystic mammary adenocarcinoma.
  • Immunohistochemical staining confirmed the presence of abundant prolactin secreting cells in the pituitary adenoma.
  • This is the second report of hyperprolactinemia with mammary dysplasia in rabbits, and the first report of cystic mammary adenocarcinoma associated with a prolactin-secreting pituitary adenoma in a rabbit.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / secretion. Mammary Neoplasms, Experimental / pathology. Prolactin / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comp Med. 2003 Aug;53(4):424-32 [14524419.001]
  • [Cites] Acta Endocrinol (Copenh). 1976 Aug;82(4):746-52 [181935.001]
  • [Cites] Breast Cancer. 2007;14(3):302-6 [17690509.001]
  • [Cites] Lab Anim Sci. 1994 Apr;44(2):114-20 [8028271.001]
  • [Cites] Cancer. 1982 Jul 1;50(1):125-9 [7200826.001]
  • (PMID = 18589874.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2704120
  •  go-up   go-down


2. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Jan;13(1):87-8
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
  • Gonadotropin-releasing hormone agonists have been proven to have a double effect on androgen metabolism: an initially stimulating, followed by an inhibitory, effect on the pituitary gland.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Neoplasms / chemically induced. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448441.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


3. Watkins RJ, Read ML, Smith VE, Sharma N, Reynolds GM, Buckley L, Doig C, Campbell MJ, Lewy G, Eggo MC, Loubiere LS, Franklyn JA, Boelaert K, McCabe CJ: Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res; 2010 May 1;70(9):3739-49
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumor transforming gene binding factor: a new gene in breast cancer.
  • Pituitary tumor transforming gene (PTTG) binding factor (PBF; PTTG1IP) is a relatively uncharacterized oncoprotein whose function remains obscure.

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Mol Biol Cell. 2009 Nov;20(21):4471-88 [19741097.001]
  • [Cites] Gene. 2000 May 2;248(1-2):41-50 [10806349.001]
  • [Cites] J Mol Endocrinol. 2000 Jun;24(3):329-38 [10828826.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):19422-7 [10781616.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5402-6 [11454683.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):277-83 [11805140.001]
  • [Cites] J Cell Sci. 2002 Dec 15;115(Pt 24):4827-41 [12432071.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2338-43 [12727860.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1631-9 [12958169.001]
  • [Cites] J Bone Miner Res. 2004 Jun;19(6):959-72 [15190888.001]
  • [Cites] Steroids. 2004 Jun;69(6):401-18 [15219790.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4222-31 [15178645.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Genomics. 1998 Apr 1;49(1):133-6 [9570958.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):985-90 [15846392.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4341-9 [15886233.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1056-61 [16384851.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1119-28 [16394085.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4344-56 [17297475.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):279-88 [18704660.001]
  • [Cites] J Biotechnol. 2009 Jan 1;139(1):6-11 [18977400.001]
  • [Cites] Endocrinology. 2009 Apr;150(4):1961-9 [19022891.001]
  • [Cites] J Cell Sci. 2009 Sep 15;122(Pt 18):3393-402 [19706688.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • (PMID = 20406982.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / G0700064; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0501548; United Kingdom / Medical Research Council / / G0601811; United Kingdom / Medical Research Council / / G0700064(81023)
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human; 4TI98Z838E / Estradiol; 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2875163; NLM/ UKMS29059
  •  go-up   go-down


Advertisement
4. Lasorella A, Rothschild G, Yokota Y, Russell RG, Iavarone A: Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol; 2005 May;25(9):3563-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Rb(+/-) mice, LOH at the wild-type Rb allele initiates pituitary adenocarcinoma, a tumor derived from embryonic melanotropes.
  • Here we identify a critical role for Id2 in initiation, growth, and angiogenesis of pituitary tumors from Rb(+/-) mice.
  • We show that proliferation and differentiation are intimately coupled in Rb(+/-) pituitary cells before tumor initiation.
  • Expression of Id2 by pituitary tumor cells promotes growth and angiogenesis by functioning as a master regulator of vascular endothelial growth factor (VEGF).

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Jan 9;22(1):1-9 [12527902.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11094-9 [12538578.001]
  • [Cites] Nature. 1999 Feb 25;397(6721):702-6 [10067894.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1040-5 [15616565.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):277-89 [14585355.001]
  • [Cites] Cell. 2003 Oct 31;115(3):281-92 [14636556.001]
  • [Cites] Nat Genet. 2003 Dec;35(4):323-30 [14625550.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2905-14 [15024078.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):513-5 [15193252.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):539-51 [15193257.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7220-5 [15492237.001]
  • [Cites] Nature. 1985 Jan 31-Feb 6;313(6001):404-6 [3855502.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):288-94 [1406932.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1021-7 [8134105.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4251-9 [7925270.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Development. 2000 Feb;127(4):693-702 [10648228.001]
  • [Cites] Genes Dev. 2000 Feb 15;14(4):391-6 [10691731.001]
  • [Cites] J Endocrinol. 2000 May;165(2):483-92 [10810312.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1900-8 [10815914.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4826-37 [10848608.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] J Neurosci. 2000 Oct 15;20(20):7648-56 [11027225.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5313-8 [12702757.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1115-29 [12695333.001]
  • [Cites] Cell. 2003 May 16;113(4):495-506 [12757710.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Neuron. 2003 Jul 3;39(1):13-25 [12848929.001]
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):410-8 [12888293.001]
  • [Cites] Angiogenesis. 2002;5(4):267-74 [12906318.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):841-53 [12910530.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4091-102 [12912908.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4260-8 [7925271.001]
  • [Cites] Genes Dev. 1994 Jun 1;8(11):1270-84 [7926730.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):2570-8 [8649364.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1870-9 [8756345.001]
  • [Cites] Dev Dyn. 1996 Nov;207(3):235-52 [8922523.001]
  • [Cites] Dev Dyn. 1997 Jan;208(1):92-106 [8989524.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8988-93 [9256422.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):865-72 [9307185.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6673-82 [9343431.001]
  • [Cites] Br J Cancer. 1997;76(12):1558-61 [9413941.001]
  • [Cites] Oncogene. 1998 Jul 9;17(1):1-12 [9671308.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5772-81 [11060028.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(12):3995-4004 [11359907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8674-9 [11447259.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):301-6 [11782392.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8326-33 [11840325.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2231-5 [11910101.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2498-502 [11980640.001]
  • [Cites] Cell. 2002 May 3;109(3):321-34 [12015982.001]
  • [Cites] Glia. 2002 Jun;38(4):329-38 [12007145.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27975-81 [12032158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404 [12177446.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):380-7 [12192596.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2530-43 [12368264.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8302-9 [12447693.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16865-70 [12486224.001]
  • (PMID = 15831462.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085628; United States / NCI NIH HHS / CA / R01 CA101644; United States / NCI NIH HHS / CA / R01 CA 101644; United States / NCI NIH HHS / CA / R01 CA 85628
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNG1 protein, human; 0 / Ccng1 protein, mouse; 0 / Cdkn1b protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin G; 0 / Cyclin G1; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Idb2 protein, mouse; 0 / Inhibitor of Differentiation Protein 2; 0 / Repressor Proteins; 0 / Retinoblastoma Protein; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC1084294
  •  go-up   go-down


5. National Toxicology Program: Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser; 2008 Jan;(545):1-240
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pituitary gland weights were significantly increased in females in the 500 ppm groups of the F(1)C and F(1)T140 study arms and in the 100 ppm group of the F(3)T21 arm.
  • In F(1)C females, there was a significant positive trend in the incidences of mammary gland adenoma or adenocarcinoma (combined) regardless of whether an unmodified or natural log-transformed dose scale was used in the analysis, and the incidence in the 500 ppm group was significantly greater than that in the control group.
  • A significant negative trend occurred in the incidences of benign mammary gland fibroadenoma in F(1)C females, and the incidence in the 500 ppm group was significantly less than that in the control group.
  • In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences.
  • When the natural log-transformed dose scale was used, a marginally significant positive trend occurred in the incidences of adenoma or adenocarcinoma (combined) in F(3)T21 females.
  • There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm.
  • There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms.
  • The incidence of benign mammary gland fibroadenoma in female rats was significantly decreased in the 500 ppm group.
  • There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on marginally increased incidences of pituitary gland neoplasms.
  • There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined).
  • [MeSH-minor] Animals. Body Weight / drug effects. Estrous Cycle / drug effects. Female. Kidney / drug effects. Kidney / pathology. Litter Size / drug effects. Longevity / drug effects. Male. Mammary Glands, Animal / drug effects. Mammary Glands, Animal / pathology. Mammary Neoplasms, Animal / chemically induced. Mammary Neoplasms, Animal / pathology. Pituitary Neoplasms / chemically induced. Pituitary Neoplasms / pathology. Pregnancy. Prenatal Exposure Delayed Effects / chemically induced. Prenatal Exposure Delayed Effects / pathology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685716.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phytoestrogens; 0 / Xenobiotics; DH2M523P0H / Genistein
  •  go-up   go-down


6. Arai A, Morishita A, Hanada Y, Aihara H: Solitary metastatic tumor within the optic chiasm--case report. Neurol Med Chir (Tokyo); 2010;50(2):158-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The bilateral optic nerves and the pituitary stalk appeared normal.
  • The histological diagnosis was adenocarcinoma, which was consistent with the primary lung cancer.
  • Suprasellar metastatic tumors to the pituitary gland, pituitary stalk, and hypothalamus are well documented, but solitary metastasis within the optic chiasm should be considered as one of several differential diagnoses of suprasellar tumors, in patients with or without a history of treated cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Neoplasm Metastasis / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185885.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. National Toxicology Program: Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study). Natl Toxicol Program Tech Rep Ser; 2008 Mar;(539):1-266
Hazardous Substances Data Bank. GENISTEIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure-related microscopic lesions were confined to males, with the mammary gland and kidney affected.
  • Incidences of mammary gland alveolar/ductal hyperplasia were significantly increased in 500 ppm males in the F(0) through F(2) generations and in 100 ppm males in the F(1) and F(2) generations.
  • In the F(3) generation, a significant positive linear exposure concentration trend in the incidences of mammary gland hyperplasia occurred, but no exposed group differed significantly from the controls in pairwise comparisons.
  • The more pronounced effect of genistein on the incidences of male mammary gland hyperplasia in the continuously exposed F(1) and F(2) generations as compared to the late adolescent and adult exposures of the F(0) generation and the preweaning-only exposure of the F(3) generation indicates that both developmental and adult exposures contribute to the maintenance of this effect into adulthood.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Female. Male. Mammary Neoplasms, Animal / chemically induced. Mammary Neoplasms, Animal / pathology. Pituitary Neoplasms / chemically induced. Pituitary Neoplasms / pathology. Pregnancy. Rats. Rats, Sprague-Dawley. Recovery of Function. Withholding Treatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685713.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Phytoestrogens; DH2M523P0H / Genistein
  •  go-up   go-down


8. Granata A, Figura M, Gulisano S, Romeo G, Sicurezza E, Failla A, Scuderi R: [Central diabetes insipidus as a first manifestation of lung adenocarcinoma]. Clin Ter; 2007 Nov-Dec;158(6):519-22
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus as a first manifestation of lung adenocarcinoma].
  • [Transliterated title] Diabete insipido centrale come prima manifestazione di adenocarcinoma polmonare.
  • The pituitary gland and infundibulum can be involved in a variety of medical conditions, including infiltrative diseases, fungal infections, tuberculosis, primary and metastatic tumors.
  • Metastases to the pituitary gland are absolutely rare, and they are generally secondary to pulmonary carcinoma in men and breast carcinoma in women.
  • Pituitary metastases more commonly affect the posterior lobe and the infundibulum than the anterior lobe.
  • The posterior lobe involvement may explain why patients with pituitary metastases frequently present with diabetes insipidus.
  • Bronchoscopy and biopsy demonstrated a pulmonary adenocarcinoma.
  • Thus, we made a diagnosis of lung cancer with local and pituitary metastases.
  • The patient received radiotherapy on the pituitary gland and adjuvant chemotherapy.
  • In conclusion, in patients presenting with sudden onset of diabetes insipidus pituitary metastases should be taken in account in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diabetes Insipidus / etiology. Lung Neoplasms / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / secondary
  • [MeSH-minor] Biopsy. Bronchoscopy. Diagnosis, Differential. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Polyuria / etiology. Thirst. Tomography, X-Ray Computed


9. Prodam F, Pagano L, Belcastro S, Golisano G, Busti A, Samà M, Caputo M, Bellone S, Voci A, Valente G, Aimaretti G: Pituitary metastases from follicular thyroid carcinoma. Thyroid; 2010 Jul;20(7):823-30
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary metastases from follicular thyroid carcinoma.
  • BACKGROUND: Metastatic carcinomas to the pituitary gland are uncommon, occurring in only 1% of the pituitary masses.
  • They often originate from breast or lung carcinomas and may resemble a nonfunctioning pituitary adenoma both clinically and radiologically.
  • Here we describe a patient with pituitary metastasis from follicular thyroid carcinoma and discuss the unique features of these lesions.
  • Pituitary magnetic resonance imaging showed a mass that was hypo-intense in T1-weighted and hyper-intense in T2-weighted-images, located from the sphenoid sinus up to chiasmatic cisterns, raising and deflecting the optic chiasm, down to hypopharynx region, and distorting the cavernous sinuses.
  • Total thyroidectomy and lymph node dissection was performed with a final histopathological diagnosis of follicular thyroid carcinoma.
  • CONCLUSIONS: Pituitary metastases from thyroid carcinoma are very uncommon.
  • As this patient illustrates, they tend to produce symptoms relating to space-occupying expansion in the parasellar region rather than to those due to destruction of the pituitary gland.
  • Although rare, pituitary metastases caused by thyroid malignancy should be considered in patients with expanding parasellar lesions if they have thyroid cancer or uncharacterized thyroid diseases.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20604687.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


10. Sidibé EH: [Pituitary carcinoma. Anatomic and clinical features of cases reported in literature]. Neurochirurgie; 2007 Aug;53(4):284-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary carcinoma. Anatomic and clinical features of cases reported in literature].
  • BACKGROUND AND PURPOSE: Pituitary gland tumors that became aggressive, implying adjacent bone structure and the brain as metastases outside of the cranial box, are referred to as pituitary carcinomas.
  • METHODS: We reviewed 67 cases reported in the literature [44 corticotropic pituitary tumors, 11 PRL tumors, 3 GH tumors, 1 TSH tumor, 3 gonadotropic cell tumors and 5 non-functioning tumors].
  • The characteristic feature is a time interval from the initial diagnosis of adenoma to that of cancer, which has ranged from 0.3 to 18 years (mean: 6.6 years; median: 5.0 years).
  • [MeSH-major] Adenocarcinoma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / diagnosis. ACTH-Secreting Pituitary Adenoma / metabolism. ACTH-Secreting Pituitary Adenoma / pathology. Adult. Aged. Female. Gonadotropins / metabolism. Growth Hormone-Secreting Pituitary Adenoma / diagnosis. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Humans. Male. Middle Aged. Prolactinoma / diagnosis. Prolactinoma / metabolism. Prolactinoma / pathology. Thyrotropin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524431.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Gonadotropins; 9002-71-5 / Thyrotropin
  • [Number-of-references] 50
  •  go-up   go-down


11. Hermet M, Delévaux I, Trouillier S, André M, Chazal J, Aumaître O: [Pituitary metastasis presenting as diabetes insipidus: a report of four cases and literature review]. Rev Med Interne; 2009 May;30(5):425-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pituitary metastasis presenting as diabetes insipidus: a report of four cases and literature review].
  • INTRODUCTION: Pituitary metastases are a rare cause of central diabetes insipidus and usually complicate advanced cancers.
  • On brain magnetic resonance imaging there was an absence of high intensity signal in the posterior pituitary lobe (one case) or an infiltration of the posterior lobe (three cases).
  • CONCLUSION: Breast and lung malignancies are the most frequent causes of metastasis of the pituitary gland.
  • A pituitary biopsy may be necessary to obtain the diagnosis.


12. Nishiyama S, Okudaira M, Saito N: Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol; 2006 Feb;80(2):88-97
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats.
  • To clarify the mechanisms behind a rolipram-induced increase in the incidence of mammary adenocarcinoma at time points earlier than 104 weeks, the hormonal changes associated with pituitary adenoma were identified, and estrous cycling in the ovary, uterus, and vagina were examined in female rats treated with rolipram for 52 weeks.
  • There was also a dose-dependent relationship with PRL-producing pituitary adenomas.
  • Together, all of the above mentioned data suggest that rolipram not only stimulates an increase in the number and size of PRL adenomas in the pituitary gland but also in the estrus phase of the estrous cycle.
  • These events might cause progression of the mammary gland tissues from hyperplasia to carcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Mammary Neoplasms, Experimental / chemically induced. Phosphodiesterase Inhibitors / toxicity. Pituitary Neoplasms / chemically induced. Prolactinoma / chemically induced. Rolipram / toxicity

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167140.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 4TI98Z838E / Estradiol; 9002-62-4 / Prolactin; K676NL63N7 / Rolipram
  •  go-up   go-down


13. Lin EY, Hsieh CT, Lin CS, Tsai TH, Chiang YH: Keyhole surgery for isolated pituitary stalk metastatic tumors: a case report and review of the literature. Minim Invasive Neurosurg; 2008 Aug;51(4):222-4
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keyhole surgery for isolated pituitary stalk metastatic tumors: a case report and review of the literature.
  • Solitary metastatic pituitary stalk tumors account for approximately less than 1% of all pituitary gland tumors and present difficulties in clinical diagnosis because most of them are clinically silent and usually too small to cause radiological changes.
  • With the advance of microsurgical techniques, keyhole surgery is indicated to obtain a specimen for pathological diagnosis and possible removal of the tumor.
  • Magnetic resonance images revealed a solitary tumor over the pituitary stalk.
  • A right supraorbital craniotomy was performed and the pathological report confirmed the diagnosis of metastatic breast cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Breast Neoplasms / pathology. Diabetes Insipidus / surgery. Pituitary Neoplasms / secondary. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Craniotomy / methods. Female. Frontal Bone / surgery. Humans. Magnetic Resonance Imaging. Minimally Invasive Surgical Procedures / methods. Neoplasm Metastasis. Neurosurgical Procedures / methods. Pituitary Gland / pathology. Pituitary Gland / surgery. Polyuria / etiology. Polyuria / pathology. Polyuria / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Insipidus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683114.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 8
  •  go-up   go-down


14. Seoane S, Ben I, Centeno V, Perez-Fernandez R: Cellular expression levels of the vitamin D receptor are critical to its transcriptional regulation by the pituitary transcription factor Pit-1. Mol Endocrinol; 2007 Jul;21(7):1513-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular expression levels of the vitamin D receptor are critical to its transcriptional regulation by the pituitary transcription factor Pit-1.
  • In the present study, it is demonstrated that administration of the pituitary transcription factor Pit-1 (originally found in the pituitary gland but also present in other nonpituitary cell types and tissues) to the MCF-7 (human breast adenocarcinoma) cell line induces a significant increase in VDR mRNA and protein levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456792.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREBBP protein, human; 0 / Histones; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; 0 / Receptors, Calcitriol; 0 / Transcription Factor Pit-1; EC 2.3.1.48 / CREB-Binding Protein; EC 2.7.7.- / RNA Polymerase II
  •  go-up   go-down


15. Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ: Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab; 2006 Nov;91(11):4603-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
  • We recently reported that the proangiogenic pituitary tumor transforming gene (PTTG) stimulates VEGF and up-regulates inhibitor of DNA binding-3 (ID3), an important gene in VEGF-dependent angiogenesis.
  • [MeSH-major] Autocrine Communication. Cell Proliferation. Inhibitor of Differentiation Proteins / physiology. Neoplasm Proteins / physiology. Thyroid Gland / physiology. Vascular Endothelial Growth Factor A / physiology. Vascular Endothelial Growth Factor Receptor-2 / physiology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Carcinoma, Papillary / metabolism. Gene Expression Regulation, Neoplastic. Growth Substances / metabolism. Humans. Mitogen-Activated Protein Kinases / metabolism. Paracrine Communication. Phosphorylation. Securin. Thyroid Neoplasms / metabolism. Tumor Cells, Cultured. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926250.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Inhibitor of Differentiation Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Vascular Endothelial Growth Factor A; 0 / pituitary tumor-transforming protein 1, human; 147785-34-0 / ID3 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


16. Santra S, Liesenfeld B, Dutta D, Chatel D, Batich CD, Tan W, Moudgil BM, Mericle RA: Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J Nanosci Nanotechnol; 2005 Jun;5(6):899-904
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a novel technique of using fluorescent silica nanoparticles (FSNPs) to detect over-expressed folate receptors, as typical for certain malignancies (metastatic adenocarcinoma, pituitary adenoma and others).

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16060150.001).
  • [ISSN] 1533-4880
  • [Journal-full-title] Journal of nanoscience and nanotechnology
  • [ISO-abbreviation] J Nanosci Nanotechnol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Coated Materials, Biocompatible; 0 / Fluorescent Dyes; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface; 7631-86-9 / Silicon Dioxide; 935E97BOY8 / Folic Acid; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


17. Granata A, Viola G, Privitera C, Romeo G, Cacciaguerra S, Gaeta M, Sicurezza E, Figuera M: Smoking, polyuria and impaired vision. Clin Nephrol; 2007 Jan;67(1):49-52
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pituitary gland can be involved in a variety of medical conditions, including metastatic tumors.
  • Metastases to the pituitary gland, although absolutely rare, more commonly affect the posterior pituitary lobe and so frequently present with diabetes insipidus.
  • CT scan of the chest showed a mass in the right superior lobe with mediastinal lymphadenopathy, with bronchoscopy and biopsy features of pulmonary adenocarcinoma.
  • The patient received radiotherapy on the pituitary gland and adjuvant chemotherapy, and as intrasellar and suprasellar mass decreased in size, urinary output was accordingly reduced.
  • Therefore, is that in patients with risk factors for cancer and sudden onset of diabetes insipidus pituitary metastasis should be taken into account in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Diabetes Insipidus, Neurogenic / etiology. Hemianopsia / etiology. Lung Neoplasms / pathology. Pituitary Neoplasms / secondary. Polyuria / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269600.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Gessl A, Vierhapper H, Feichtinger H: Non-suppressible TSH in a patient thyroidectomized due to follicular thyroid carcinoma. Exp Clin Endocrinol Diabetes; 2006 Jul;114(7):389-92
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a female patient with follicular thyroid carcinoma in whom, under intended levothyroxin suppression therapy, a TSH-PRL-producing pituitary adenoma manifested by failure to achieve adequate TSH suppression, subtle signs of hyperthyroidism,and finally symptoms of elevated PRL.
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Adult. Female. Humans. Pituitary Gland / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915543.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


19. Gallego R, Pintos E, García-Caballero T, Raghay K, Boulanger L, Beiras A, Gaudreau P, Morel G: Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers. Histol Histopathol; 2005 07;20(3):697-706
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Growth hormone releasing hormone receptor (GHRH-R) mRNA and protein was first localized to the anterior pituitary gland, consequent with the action of its ligand on GH synthesis and release.
  • [MeSH-major] Breast Neoplasms / metabolism. Ovary / metabolism. Prostatic Neoplasms / metabolism. Receptors, Neuropeptide / metabolism. Receptors, Pituitary Hormone-Regulating Hormone / metabolism. Testis / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Mammary Glands, Human / metabolism. Placenta / metabolism. Pregnancy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944917.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor
  •  go-up   go-down


20. Perez-Fernandez R, Seoane S, Garcia-Caballero T, Segura C, Macia M: Vitamin D, Pit-1, GH, and PRL: possible roles in breast cancer development. Curr Med Chem; 2007;14(29):3051-8
MedlinePlus Health Information. consumer health - Vitamin D.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have explored the role of 1,25-(OH)(2)D(3) in cell growth and differentiation in normal and tumoral mammary gland, in which it shows antiproliferative effects.
  • The pituitary transcription factor-1 (Pit-1), which in the pituitary is critical to both cell differentiation and PRL and GH transcription, has been recently found in normal and tumoral human breast tissue, with mRNA expression levels significantly higher in tumors than in normal breast.
  • As in the pituitary, Pit-1 regulates mammary GH and PRL secretion, increases cell proliferation and decreases apoptosis.
  • 1,25-(OH)(2)D(3) administration to the MCF-7 human breast adenocarcinoma cell line significantly reduces Pit-1 expression, suggesting that inhibition of Pit-1 expression by 1,25-(OH)(2)D(3) may reduce the increase in proliferation induced by this transcription factor directly or indirectly through increased GH and/or PRL expression.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line. Cell Line, Tumor. Humans. Mammary Glands, Animal / growth & development. Mammary Glands, Animal / metabolism. Mammary Glands, Animal / physiology. Mammary Glands, Human / growth & development. Mammary Glands, Human / metabolism. Pituitary Gland / metabolism. Receptors, Calcitriol / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220741.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Transcription Factor Pit-1; 12629-01-5 / Human Growth Hormone; 1406-16-2 / Vitamin D; 9002-62-4 / Prolactin
  • [Number-of-references] 157
  •  go-up   go-down


21. Kasamatsu A, Endo Y, Uzawa K, Nakashima D, Koike H, Hashitani S, Numata T, Urade M, Tanzawa H: Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int J Biochem Cell Biol; 2005 Sep;37(9):1869-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic carcinoma (ACC) of the salivary gland often has a variable clinical course with a poor prognosis.
  • To investigate DNA copy number aberrations associated with ACCs, we compared comparative genome hybridization data from ACCs (n = 6) with other types of salivary gland tumors such as adenocarcinomas (n = 3) and pleomorphic adenomas (n = 6).
  • In addition, we identified pituitary tumor-transforming gene 1 and transformation related protein 63 genes that were up-regulated by increasing DNA copy number and modulated expression of oncogenes.
  • These results suggested that the combination of copy number and gene expression profiling provides an improved strategy for gene identification in salivary gland ACCs.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Gene Expression Profiling. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908262.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  •  go-up   go-down


22. Autorino R, Zito A, Di Giacomo F, Cosentino L, Quarto G, Di Lorenzo G, Mordente S, Pane U, Giordano A, D'Armiento M: Orbital metastasis as a first indication of prostate cancer: a case report. Arch Ital Urol Androl; 2005 Jun;77(2):109-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gadolinium-MRI scans of the head revealed a left osteoblastic intrasellar mass, displacing the pituitary gland.
  • Transrectal ultrasound-guided biopsy revealed prostatic adenocarcinoma (Gleason score 4+3) in both lobes of the prostate.
  • However the disease subsequently progressed and the patient died 22 months after diagnosis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146273.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Fertility Agents, Female; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


23. Jung JW, Noh GY, Lee TH, Lee YY, Yi KH, Kim CH, Lee JC: Polyuria and polydipsia in a patient with non-small-cell lung cancer. Clin Lung Cancer; 2007 Nov;8(9):565-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor metastasis to the pituitary gland has been infrequently reported, and this is probably because only a small proportion of these patients are symptomatic.
  • A 78-year-old man was diagnosed 2 years previously with stage IIIA adenocarcinoma of the lung and treated with sequential chemoradiation therapy and later with whole-brain radiation therapy because of newly developed brain metastasis; he was then admitted to our hospital with symptoms of polydipsia and polyuria.
  • He was confirmed to have central diabetes insipidus that was caused by the pituitary metastasis from lung cancer.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Diabetes Insipidus, Neurogenic. Lung Neoplasms / pathology. Pituitary Neoplasms / secondary


24. de Ostrovich KK, Lambertz I, Colby JK, Tian J, Rundhaug JE, Johnston D, Conti CJ, DiGiovanni J, Fuchs-Young R: Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am J Pathol; 2008 Sep;173(3):824-34
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the role of IGF-1 in mammary tumorigenesis in vivo, we used transgenic mice in which overexpression of IGF-1 is under the control of the bovine keratin 5 (BK5) promoter and is directed to either the myoepithelial or basal cells in a variety of organs, including the mammary gland.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 May 15;63(10):2425-33 [12750262.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Mol Endocrinol. 1989 Mar;3(3):509-17 [2747657.001]
  • [Cites] J Biol Chem. 1990 Dec 5;265(34):21172-8 [2174437.001]
  • [Cites] Carcinogenesis. 1990 Dec;11(12):2245-51 [2265476.001]
  • [Cites] Lancet. 1992 Jan 4;339(8784):1-15 [1345950.001]
  • [Cites] Mol Endocrinol. 1993 Jun;7(6):743-52 [7689695.001]
  • [Cites] Mol Endocrinol. 1994 Apr;8(4):510-7 [8052269.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):321-30 [8536631.001]
  • [Cites] Mutat Res. 1995 Dec;333(1-2):29-35 [8538632.001]
  • [Cites] Environ Health Perspect. 1996 Sep;104(9):938-67 [8899375.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):154-61 [8995241.001]
  • [Cites] J Endocrinol. 1997 Jan;152(1):39-47 [9014838.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):459-64 [9067542.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):553-9 [9067556.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] J Androl. 1997 Nov-Dec;18(6):602-11 [9432133.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Endocrine. 1998 Jun;8(3):251-9 [9741830.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):575-84 [15681840.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):155-62 [11169863.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):311-6 [11577173.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60 [10737798.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1561-70 [10749124.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):7-17 [10791764.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):19-30 [10791765.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):31-42 [10791766.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1224-8 [10882860.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):204-17 [11988840.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2673-9 [12072401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jun;74(3):199-211 [12206512.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):130-8 [12218293.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47645-52 [12364325.001]
  • [Cites] Breast Cancer Res. 2002;4(6):231-9 [12473169.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3781-7 [15867374.001]
  • [Cites] Mol Carcinog. 2005 Oct;44(2):137-45 [16086373.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):273-8 [16728563.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):583-92 [16728584.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):584-94 [17050554.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):763-8 [17416768.001]
  • [Cites] Pituitary. 2007;10(2):129-33 [17487588.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):659-72 [17721431.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10879-88 [18006833.001]
  • [Cites] Exp Cell Res. 2002 Feb 1;273(1):107-17 [11795951.001]
  • [Cites] Oncology. 1999 Nov;57(4):330-40 [10575321.001]
  • [Cites] Mol Carcinog. 2000 Jan;27(1):10-7 [10642432.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):889-98 [10702797.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21695-702 [10777488.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35893-901 [10967123.001]
  • [Cites] J Endocrinol. 2000 Aug;166(2):329-38 [10927622.001]
  • [Cites] J Nutr. 1979 May;109(5):925-6 [438904.001]
  • (PMID = 18688034.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA037111; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA 104114; United States / NCI NIH HHS / CA / R01 CA104114; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NCI NIH HHS / CA / CA37111; United States / NIEHS NIH HHS / ES / ES07784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136601-57-5 / Cyclin D1; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2527085
  •  go-up   go-down


25. Meij BP, Auriemma E, Grinwis G, Buijtels JJ, Kooistra HS: Successful treatment of acromegaly in a diabetic cat with transsphenoidal hypophysectomy. J Feline Med Surg; 2010 May;12(5):406-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography revealed a thick palatum molle and an enlarged pituitary gland, indicating a pituitary neoplasm.
  • Microsurgical transsphenoidal hypophysectomy was performed and microscopic examination of the surgical specimen revealed an acidophilic, infiltrative pituitary adenoma that showed positive immunostaining for GH.
  • PRACTICAL RELEVANCE: This is the first report detailing transsphenoidal hypophysectomy as a feasible and effective treatment for feline acromegaly due to a pituitary somatotroph adenoma.
  • [MeSH-major] Acromegaly / veterinary. Adenocarcinoma / veterinary. Cat Diseases / surgery. Hypophysectomy / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20417901.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


26. Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ: Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev; 2010 Sep;19(9):2298-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 1994 and 2006, 187 incident cases of pancreatic adenocarcinoma occurred (follow-up of up to 11.7 years).
  • [MeSH-minor] Adenocarcinoma / blood. Aged. Case-Control Studies. Cohort Studies. Early Detection of Cancer / methods. Female. Humans. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • Genetic Alliance. consumer health - Pancreatic cancer 3.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] Biochem Biophys Res Commun. 2003 Feb 28;302(1):46-55 [12593846.001]
  • [Cites] J Surg Oncol. 2003 Jan;82(1):51-6 [12501168.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704 [14710348.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):3941-8 [14604996.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):438-44 [15006921.001]
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):584-8 [15122592.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):103-7 [2152769.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Feb;80(2):443-9 [7531712.001]
  • [Cites] Horm Res. 1994;42(4-5):145-51 [7532613.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2007-11 [7743492.001]
  • [Cites] Endocr Rev. 1995 Feb;16(1):3-34 [7758431.001]
  • [Cites] J Endocrinol. 1996 Jun;149(3):367-72 [8691094.001]
  • [Cites] Am J Clin Nutr. 1996 Oct;64(4):650-8 [8839517.001]
  • [Cites] Endocr Rev. 1997 Dec;18(6):801-31 [9408744.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 1998 May;53(3):M176-82 [9597048.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2953-65 [15517902.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):203-20 [15650828.001]
  • [Cites] Pituitary. 2007;10(2):129-33 [17487588.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):98-104 [17533398.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7923-8 [17699799.001]
  • [Cites] Public Health Nutr. 2008 Feb;11(2):183-95 [17610761.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):371-9 [19030972.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3467-73 [19064563.001]
  • [Cites] Drugs Aging. 2000 Jan;16(1):29-40 [10733262.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):403-12 [10794485.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • (PMID = 20699371.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010202-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ NIHMS219782; NLM/ PMC2936681
  •  go-up   go-down


27. Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC: Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol; 2005 Jun;26(6):1629-35
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasoactive intestinal peptide (VIP) functions as a mitogenic agent in the human prostate gland acting by autocrine/paracrine mechanisms.
  • RT-PCR showed the expression of mRNA for VIP in normal and malignant tissues, whereas VIP levels, as measured by enzyme immuno-analysis, were about two times higher in adenocarcinoma samples.
  • Real-time RT-PCR indicated a minor expression of VPAC2 receptors in the prostate gland, as well as the overexpression of VPAC1 and PAC1 receptors in malignant tissue specimens.
  • [MeSH-minor] Aged. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / analysis. Receptors, Cell Surface / analysis. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I. Receptors, Vasoactive Intestinal Peptide, Type II. Receptors, Vasoactive Intestinal Polypeptide, Type I. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870879.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADCYAP1R1 protein, human; 0 / JV 1-53; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; 0 / Receptors, Vasoactive Intestinal Peptide; 0 / Receptors, Vasoactive Intestinal Peptide, Type II; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 0 / VIPR1 protein, human; 0 / VIPR2 protein, human; 37221-79-7 / Vasoactive Intestinal Peptide; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


28. Ayberk G, Ozveren MF, Yildirim T, Ercan K, Cay EK, Koçak A: Review of a series with abducens nerve palsy. Turk Neurosurg; 2008 Oct;18(4):366-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The causes of the abducens nerve paralysis of our patients were as follows: two cases with head trauma, three cases with pituitary tumors, one case with sphenoid sinus mucocele, one case with greater superficial petrosal nerve cellular schwannoma at the petrous apex, one case with hypertensive intraventricular hemmorhage, one case with hydrocephalus, and one case with parotid tumor and skull base/brain stem invasion.
  • RESULTS: Depending on the location of the lesion, the symptoms due to nuclear damage showed no improvement as in our case with adenocarcinoma of the parotid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107682.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


29. Uchihara T, Okubo C, Tanaka R, Minami Y, Inadome Y, Iijima T, Morishita Y, Fujita J, Noguchi M: Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma. J Thorac Oncol; 2007 Sep;2(9):796-801
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Neuronatin is a protein that is specifically expressed in the nervous system in the course of embryonal brain development, and its expression is limited to the pituitary gland in normal human adults.
  • METHODS: We determined the frequency of neuronatin expression in surgically resected samples from non-small cell lung carcinoma (51 adenocarcinoma and 41 squamous cell carcinoma) by immunohistochemical staining, and investigated the correlations between expression level and various clinicopathological features.
  • RESULTS: Expression of neuronatin was observed more frequently in squamous cell carcinoma (63%) than in adenocarcinoma (25%).
  • In both adenocarcinoma and squamous cell carcinoma, less differentiated tumors expressed neuronatin more frequently than did differentiated tumors.
  • In adenocarcinoma, but not squamous cell carcinoma, the prognosis of neuronatin-positive cases was significantly worse than that of neuronatin-negative cases.
  • CONCLUSION: Neuronatin expression is specific for tumor tissue and was detected in both pulmonary adenocarcinoma and squamous cell carcinoma at high frequency, particularly in less differentiated tumors.
  • Neuronatin expression is associated with poor prognosis in patients with adenocarcinoma, and may be useful as a prognostic marker for lung adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805055.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / NNAT protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


30. Gil-Puig C, Seoane S, Blanco M, Macia M, Garcia-Caballero T, Segura C, Perez-Fernandez R: Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation. Eur J Endocrinol; 2005 Aug;153(2):335-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The transcription factor pituitary-1 (Pit-1) is mainly expressed in the pituitary gland, where it has critical roles in cell differentiation and as a transcriptional factor for GH and prolactin (PRL).
  • It is also expressed in human extrapituitary tissues (placenta, lymphoid and haematopoietic tissues) and cell lines (human breast adenocarcinoma cells, MCF-7).
  • Despite the widely suggested roles of GH and PRL in the progression of proliferative mammary disorders, Pit-1 expression in human mammary gland has not yet been reported.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061841.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / POU1F1 protein, human; 0 / RNA, Messenger; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


31. Ortín A, Ferrer LM, Loste A, García de Jalón JA, Gómez P, Ramos JJ: Coexistence of pituitary adenocarcinoma and intraocular melanoma in a sheep. Vet Rec; 2006 Nov 18;159(21):718-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of pituitary adenocarcinoma and intraocular melanoma in a sheep.
  • [MeSH-major] Adenocarcinoma / veterinary. Eye Neoplasms / veterinary. Melanoma / veterinary. Pituitary Neoplasms / veterinary. Sheep Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114384.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Riemenschneider MJ, Beseoglu K, Hänggi D, Reifenberger G: Prostate adenocarcinoma metastasis in the pituitary gland. Arch Neurol; 2009 Aug;66(8):1036-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate adenocarcinoma metastasis in the pituitary gland.
  • [MeSH-major] Adenocarcinoma / secondary. Pituitary Neoplasms / secondary. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Diagnosis, Differential. Diplopia / etiology. Endoscopy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667229.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement